Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14187MR)

This product GTTS-WQ14187MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14187MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6211MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ5576MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ14509MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ6707MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ960MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ2915MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ4504MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ10485MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2951742
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW